Citric acid monohydrate 4.8 mg/mL - etsinnän tulokset

Australia - englanti - Department of Health (Therapeutic Goods Administration)

posaconazole suspension arx posaconazole 40 mg/ml oral suspension bottle

arrotex pharmaceuticals pty ltd - posaconazole, quantity: 40 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; sodium citrate dihydrate; citric acid monohydrate; titanium dioxide; glycerol; xanthan gum; liquid glucose; peg-40 hydrogenated castor oil; purified water; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; flavour - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: ? treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

andrews effervescent antacid

glaxosmithkline nz limited - citric acid monohydrate 19%; magnesium sulfate heptahydrate 17%; sodium bicarbonate 23% - effervescent powder - active: citric acid monohydrate 19% magnesium sulfate heptahydrate 17% sodium bicarbonate 23% excipient: sucrose